| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Pediatric Branch [K. G. B., M. I. G., I. T. M.], Clinical Oncology Program, and Molecular Genetics Section [K. H., D. S.], Laboratory of Genetics, National Cancer Institute, Bethesda, Maryland 20892
Available evidence suggests that, among hematological malignancies, p53 is most often mutated in Burkitt's lymphoma (BL). However, much of the published data is based on cell lines. We have, therefore, analyzed BL biopsies to determine more accurately the frequency and pattern of p53 mutations in primary tumors and to determine whether there are differences among the various subtypes of BL. Among 27 BL biopsies from South America, we have observed mutations in the p53 gene (exons 5 through 8) in 37% of tumors. The higher frequency of mutations in cell lines (70%) suggests that mutation of p53 may be associated with tumor progression. Summarizing available data we conclude that the presence of mutated p53 in BL is independent of the geographic origin of the tumor, the 8;14 chromosomal breakpoint locations and Epstein-Barr virus association. We also find that the mutational spectrum of p53 in BL differs from that observed in nonlymphoid tumors. More than 50% of mutations in BL are clustered in a small stretch of 33 amino acids (codons 213 to 248). Interestingly, codon 213 appears to be as frequently mutated as codon 248. Conversely, codon 273, often mutated in solid tumors, is rarely involved in BL.
1 To whom requests for reprints should be addressed, at National Institutes of Health, National Cancer Institute-POB, Building 10, Room 13N240, Bethesda, MD 20892.
2 Supported by a Fellowship from the Cancer Research Foundation of America.
Received 4/15/92. Accepted 6/15/92.
This article has been cited by other articles:
|
|
 |
|
  K. T. Bieging, A. C. Amick, and R. Longnecker Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis PNAS, October 20, 2009; 106(42): 17945 - 17950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Blum, G. Lozanski, and J. C. Byrd Adult Burkitt leukemia and lymphoma Blood, November 15, 2004; 104(10): 3009 - 3020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. I. Gutierrez, M. M. Ibrahim, J. K. Dale, T. C. Greiner, S. E. Straus, and K. Bhatia Discrete Alterations in the BZLF1 Promoter in Tumor and Non-Tumor-Associated Epstein-Barr Virus J Natl Cancer Inst, December 4, 2002; 94(23): 1757 - 1763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Braziel, D. A. Arber, M. L. Slovak, M. L. Gulley, C. Spier, C. Kjeldsberg, J. Unger, T. P. Miller, R. Tubbs, C. Leith, et al. The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features Blood, June 15, 2001; 97(12): 3713 - 3720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Buller, T. A. Lallas, M. S. Shahin, A. K. Sood, M. Hatterman-Zogg, B. Anderson, J. I. Sorosky, and P. A. Kirby The p53 Mutational Spectrum Associated with BRCA1 Mutant Ovarian Cancer Clin. Cancer Res., April 1, 2001; 7(4): 831 - 838. [Abstract] [Full Text]
|
|
|
|
|
|
U. Klangby, I. Okan, K. P. Magnusson, M. Wendland, P. Lind, and K. G. Wiman p16/INK4a and p15/INK4b Gene Methylation and Absence of p16/INK4a mRNA and Protein Expression in Burkitt's Lymphoma Blood, March 1, 1998; 91(5): 1680 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Uittenbogaard, H. A. Giebler, D. Reisman, and J. K. Nyborg Transcriptional Repression of p53 by Human T-cell Leukemia Virus Type I Tax Protein J. Biol. Chem., December 1, 1995; 270(48): 28503 - 28506. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
